Dizal (Jiangsu) Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Dizal (Jiangsu) Pharmaceutical has a total shareholder equity of CN¥696.6M and total debt of CN¥521.4M, which brings its debt-to-equity ratio to 74.9%. Its total assets and total liabilities are CN¥1.6B and CN¥855.6M respectively.
Key information
74.9%
Debt to equity ratio
CN¥521.42m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥816.91m |
| Equity | CN¥696.59m |
| Total liabilities | CN¥855.65m |
| Total assets | CN¥1.55b |
Recent financial health updates
Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?
Aug 20
Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?
Apr 30Recent updates
Financial Position Analysis
Short Term Liabilities: 688192's short term assets (CN¥978.9M) exceed its short term liabilities (CN¥544.7M).
Long Term Liabilities: 688192's short term assets (CN¥978.9M) exceed its long term liabilities (CN¥310.9M).
Debt to Equity History and Analysis
Debt Level: 688192 has more cash than its total debt.
Reducing Debt: 688192's debt to equity ratio has increased from 0% to 74.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688192 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688192 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.